1-4 of 4
Xinglei Chai
Close
Sort by
Journal Articles

Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective

Keith W. Pratz, Xinglei Chai, Jipan Xie, Lei Yin, Xiaoyu Nie, Melissa Montez, Erica Iantuono, Lisa Downs, Esprit Ma
Journal: Blood
Blood (2021) 138 (Supplement 1): 112.
https://doi.org/10.1182/blood-2021-148338
Published: 2021
Journal Articles

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Xinglei Chai, PhD, Cynthia Z. Qi, MBA, Eric Q Wu
Journal: Blood
Blood (2019) 134 (Supplement_1): 3419.
https://doi.org/10.1182/blood-2019-129070
Published: 2019
Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu
Journal: Blood
Blood (2019) 134 (Supplement_1): 4723.
https://doi.org/10.1182/blood-2019-129215
Published: 2019
Journal Articles

Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective

Zheng-Yi Zhou, PhD, Kejal Parikh, Xinglei Chai, Ariel Rokito, Chuka Udeze, Jipan Xie, Amit Agarwal
Journal: Blood
Blood (2018) 132 (Supplement 1): 3535.
https://doi.org/10.1182/blood-2018-99-112942
Published: 2018